Patents by Inventor Maier Lorizate

Maier Lorizate has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for blocking HIV entry into dendritic cells by inhibiting sialoadhesin-sialyllactose binding interactions with gangliosides
    Patent number: 9789130
    Abstract: The present invention refers to methods and compositions to prevent viral entry into cells expressing the CD169/sialoadhesin surface receptor by inhibiting the coupling of the sialyllactose molecule contained in the viral membrane gangliosides to the CD 169/sialoadhesin receptor. The invention also pertains to vaccine compositions based on dendritic cells loaded with an antigen of interest whereby the vaccine is provided together with a composition capable of preventing viral entry into cells expressing the CD169/sialoadhesin. Moreover, the invention relates to diagnostic and therapeutic compositions that can be specifically delivered to enveloped virions wherein the diagnostic/therapeutic agent is coupled to CD169/sialoadhesin.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: October 17, 2017
    Assignees: LABORATORIOS DEL DR. ESTEVE, S.A., FUNDACIÓ PRIVADA INSTITUT DE RECERCA DE LA SIDA—CAIXA, INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS, RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG
    Inventors: Nuria Izquierdo Useros, Hans-Georg Krauesslich, Maier Lorizate, Javier Martinez Picado
  • INHIBITORS OF SIALOADHESIN FOR THE TREATMENT OF DISEASES CAUSED BY ENVELOPED VIRUSES
    Publication number: 20140370052
    Abstract: The present invention refers to methods and compositions to prevent viral entry into cells expressing the CD169/sialoadhesin surface receptor by inhibiting the coupling of the sialyllactose molecule contained in the viral membrane gangliosides to the CD 169/sialoadhesin receptor. The invention also pertains to vaccine compositions based on dendritic cells loaded with an antigen of interest whereby the vaccine is provided together with a composition capable of preventing viral entry into cells expressing the CD169/sialoadhesin. Moreover, the invention relates to diagnostic and therapeutic compositions that can be specifically delivered to enveloped virions wherein the diagnostic/therapeutic agent is coupled to CD169/sialoadhesin.
    Type: Application
    Filed: December 17, 2012
    Publication date: December 18, 2014
    Inventors: Nuria Izquierdo Useros, Hans-Georg Krauesslich, Maier Lorizate, Javier Martinez Picado
  • Non-proteolysable oligopeptides that inhibit glycoprotein GP41 of the aids virus
    Patent number: 8110545
    Abstract: The invention relates to non-proteolysable oligopeptides that inhibit glycoprotein 41 of the AIDS virus. More specifically, the invention relates to the identification of oligopeptides, particularly hexapeptides, (D), (L) or mixed, preferably D-hexapeptides, which inhibit the binding of a retrovirus to a target cell, thereby providing novel therapies against infection from the human immunodeficiency virus (HIV). The invention also relates to the use of said D-hexapeptides in the form of single components or complex mixtures as prophylactic or therapeutic agents for retroviral infections, especially human immunodeficiency virus type 1 (HIV-1).
    Type: Grant
    Filed: December 29, 2006
    Date of Patent: February 7, 2012
    Assignees: Universidad Del Pais Vasco, Universidad de Valencia
    Inventors: Jose Luis Nieva Escandon, Maria Jose Gomara Elena, Maier Lorizate Nogales, Nerea Huarte Arrayago, Ismael Mingarro Munoz, Enrique Perez Paya
  • NON-PROTEOLYSABLE OLIGOPEPTIDES THAT INHIBIT GLYCOPROTEIN GP41 OF THE AIDS VIRUS
    Publication number: 20100197606
    Abstract: The invention relates to non-proteolysable oligopeptides that inhibit glycoprotein 41 of the AIDS virus. More specifically, the invention relates to the identification of oligopeptides, particularly hexapeptides, (D), (L) or mixed, preferably D-hexapeptides, which inhibit the binding of a retrovirus to a target cell, thereby providing novel therapies against infection from the human immunodeficiency virus (HIV). The invention also relates to the use of said D-hexapeptides in the form of single components or complex mixtures as prophylactic or therapeutic agents for retroviral infections, especially human immunodeficiency virus type 1 (HIV-1).
    Type: Application
    Filed: December 29, 2006
    Publication date: August 5, 2010
    Inventors: José Luis Nieva Escandón, Maria José Gómara Elena, Maier Lorizate Nogales, Nerea Huarte Arrayago, Ismael Mingarro Munoz, Enrique Pérez Paya